Investor Relations

NKGen strives to bring transformative NK cell therapies to patients with neurodegenerative diseases and cancer.

Our Mission and Vision

NKGen Biotech’s mission is to improve patient outcomes in neurodegenerative disease and cancer by developing safe and effective cellular therapies that leverage the power of a patient’s immune system. NKGen’s vision is to become the global leader in NK cell therapies.

Corporate Profile

NKGen Biotech is a clinical-stage biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. NKGen’s product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells with increased activity (defined by parameters such as cytotoxicity, cytokine production and activating receptor expression) as compared to the starting NK cell population.

SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. NKGen believes that SNK cells have the potential to deliver transformational benefits to patients with both neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, and cancer.

Guided by Science

NKGen Biotech’s industry-leading management team, board of directors and scientific advisors have significant expertise across every aspect of our business. Our scientific advisors, with deep experience in immunology, neurology and oncology, help us advance our clinical trial programs with the goal of bringing life changing NK cell therapies to patients in need.

Latest Press Releases

NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer’s Trial with Activation of Clinical Sites in Canada and Florida

NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations

NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Email Alerts

Contact IR

NKGen Biotech is located in Orange County, California a thriving industry hub for innovative biomedical and life science companies.

NKGen Biotech, Inc.
3001 Daimier Street
Santa Ana, CA 94080
investors@nkgenbiotech.com